Guangzhou Consun Pharmaceutical Research

Guangzhou Consun Pharmaceutical Research Co., Ltd. is the dedicated research and development subsidiary of Consun Pharmaceutical Group, a leading modern pharmaceutical enterprise in China specializing in nephrology. Established in 2005, the company focuses on the discovery and development of both innovative small molecule chemical drugs and modern traditional Chinese medicines (TCM). Its pipeline features promising candidates such as SK-08, a novel soluble guanylyl cyclase (sGC) activator, and SK-09, a TRPC5 inhibitor targeting podocyte injury-related renal diseases. Through its state-of-the-art R&D center and collaborations with top academic institutions, Guangzhou Consun Pharmaceutical Research aims to deliver advanced therapeutic solutions for chronic kidney disease, diabetic nephropathy, and other critical medical conditions.